secwatch / observer
8-K filed January 25, 2023, 6:59 PM ET ticker VIR CIK 0001706431
leadership confidence high sentiment neutral materiality 0.60

Vir Biotechnology appoints Marianne De Backer as CEO effective April 3, 2023; George Scangos retires

Vir Biotechnology, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Marianne De Backer

Class II director
VIR · Vir Biotechnology, Inc.
Effective
2023-04-03
Filed
January 25, 2023, 6:59 PM ET
In addition, effective as of the Effective Date, the size of the Board will increase to 11 directors and Dr. De Backer will be appointed to fill the newly created vacancy to serve on the Board as a Class II director until the Company’s 2024 annual meeting of stockholders, and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.
Departed

George Scangos

Chief Executive Officer and President
VIR · Vir Biotechnology, Inc.
Effective
2023-04-03
Successor
Marianne De Backer
Filed
January 25, 2023, 6:59 PM ET
On January 19, 2023, George Scangos, Ph.D., notified the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) of his decision to retire as Chief Executive Officer and President effective as of the Effective Date (as defined below).
Appointed

Marianne De Backer

Chief Executive Officer
VIR · Vir Biotechnology, Inc.
Effective
2023-04-03
Filed
January 25, 2023, 6:59 PM ET
On January 19, 2023, the Board appointed Marianne De Backer, MSc, Ph.D., MBA, as Chief Executive Officer of the Company, effective as of April 3, 2023 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marianne De Backer was appointed as Class II director at Vir Biotechnology, Inc..

Action
appointed
Role
Class II director
Exact text from the filing
In addition, effective as of the Effective Date, the size of the Board will increase to 11 directors and Dr. De Backer will be appointed to fill the newly created vacancy to serve on the Board as a Class II director until the Company’s 2024 annual meeting of stockholders, and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

George Scangos retired as Chief Executive Officer and President at Vir Biotechnology, Inc..

Action
retired
Role
Chief Executive Officer and President
Exact text from the filing
On January 19, 2023, George Scangos, Ph.D., notified the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) of his decision to retire as Chief Executive Officer and President effective as of the Effective Date (as defined below).
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Marianne De Backer was appointed as Chief Executive Officer at Vir Biotechnology, Inc..

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
On January 19, 2023, the Board appointed Marianne De Backer, MSc, Ph.D., MBA, as Chief Executive Officer of the Company, effective as of April 3, 2023 (the “Effective Date”).
View on SEC.gov

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-014834
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.